2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Marina Kremyanskaya, MD, PhD, discusses the design of the phase 1/2 MANIFEST trial in myelofibrosis.
Marina Kremyanskaya, MD, PhD, assistant professor of medicine, hematology, and medical Oncology, Icahn School of Medicine, Mount Sinai, medical director, Inpatient Oncology Unit, The Mount Sinai Hospital, discusses the design of the phase 1/2 MANIFEST trial (NCT02158858) in myelofibrosis.
Pelabresib is an investigational oral small molecule inhibitor of bromodomain 1/2 of BET proteins, Kremyanskaya says. During the 2021 ASH Annual Meeting and Exposition, updated findings from arm 1 of the MANIFEST trial were presented. The results demonstrated clinical and exploratory activity with pelabresib in patients with advanced myelofibrosis who were refractory to, ineligible for, or intolerant of ruxolitinib (Jakafi).
In addition to arm 1, the trial is evaluating pelabresib in combination with ruxolitinib as first-line treatment for JAK inhibitor–naïve patients with myelofibrosis and as a second-line add-on treatment for patients who had a suboptimal response to or progression on ruxolitinib, Kremyanskaya concludes.